MX2010003916A - Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). - Google Patents
Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).Info
- Publication number
- MX2010003916A MX2010003916A MX2010003916A MX2010003916A MX2010003916A MX 2010003916 A MX2010003916 A MX 2010003916A MX 2010003916 A MX2010003916 A MX 2010003916A MX 2010003916 A MX2010003916 A MX 2010003916A MX 2010003916 A MX2010003916 A MX 2010003916A
- Authority
- MX
- Mexico
- Prior art keywords
- spiropyrrolidines
- hiv infection
- use against
- against hcv
- hcv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente solicitud describe compuestos orgánicos que son útiles para el tratamiento, la prevención y/o la mejoría de enfermedades humanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97897407P | 2007-10-10 | 2007-10-10 | |
PCT/EP2008/063460 WO2009047264A1 (en) | 2007-10-10 | 2008-10-08 | Spiropyrrolidines and their use against hcv and hiv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010003916A true MX2010003916A (es) | 2010-05-05 |
Family
ID=40243948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003916A MX2010003916A (es) | 2007-10-10 | 2008-10-08 | Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). |
Country Status (20)
Country | Link |
---|---|
US (2) | US8008263B2 (es) |
EP (1) | EP2205584A1 (es) |
JP (1) | JP5095824B2 (es) |
KR (2) | KR101218882B1 (es) |
CN (2) | CN101868452B (es) |
AR (1) | AR068756A1 (es) |
AU (1) | AU2008309589B2 (es) |
BR (1) | BRPI0817881A2 (es) |
CA (1) | CA2702132A1 (es) |
CL (1) | CL2008002995A1 (es) |
CO (1) | CO6270317A2 (es) |
CR (1) | CR11310A (es) |
EA (1) | EA020951B1 (es) |
MA (1) | MA31767B1 (es) |
MX (1) | MX2010003916A (es) |
PE (1) | PE20091237A1 (es) |
TN (1) | TN2010000137A1 (es) |
TW (1) | TW200932737A (es) |
WO (1) | WO2009047264A1 (es) |
ZA (1) | ZA201001585B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA100666C2 (uk) * | 2006-04-11 | 2013-01-25 | Новартіс Аг | Інгібітори нсv/віл та їх застосування |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
WO2009082697A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
EP2237666A4 (en) | 2007-12-21 | 2012-05-16 | Avila Therapeutics Inc | HCV PROTEASE INHIBITORS AND USES THEREOF |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
AU2009303483A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
IN2012DN02693A (es) * | 2009-09-28 | 2015-09-04 | Intermune Inc | |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
WO2012048235A1 (en) * | 2010-10-08 | 2012-04-12 | Novartis Ag | Vitamin e formulations of sulfamide ns3 inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
TW201408669A (zh) | 2012-08-08 | 2014-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9416139B2 (en) | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
CN103848818B (zh) | 2012-11-29 | 2017-03-15 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用 |
WO2014082381A1 (en) * | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
RS62860B1 (sr) | 2014-09-17 | 2022-02-28 | Zymeworks Inc | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih |
WO2019123285A1 (en) | 2017-12-20 | 2019-06-27 | Novartis Ag | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals |
IL302990A (en) | 2020-11-23 | 2023-07-01 | Enanta Pharm Inc | Antivirals that are derivatives of the novel spiropyrrolidine |
US20240051950A1 (en) * | 2020-12-22 | 2024-02-15 | The Regents Of The University Of California | Novel CYP3A4-Specific Inhibitors and Methods of Using Same |
WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
WO2023003610A1 (en) * | 2021-07-23 | 2023-01-26 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
KR20040077767A (ko) * | 2002-01-23 | 2004-09-06 | 쉐링 코포레이션 | C형 간염 바이러스 감염 치료용 ns3-세린 프로테아제억제제로서의 프롤린 화합물 |
SG180022A1 (en) * | 2003-06-17 | 2012-05-30 | Schering Corp | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
CN1867579A (zh) * | 2003-08-26 | 2006-11-22 | 先灵公司 | 丙肝病毒的新的肽模拟物ns3-丝氨酸蛋白酶抑制剂 |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
TW200526686A (en) * | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
SI1677827T1 (sl) * | 2003-10-27 | 2009-06-30 | Vertex Pharma | Zdravilni sestavek proti virusu hepatitisa c (hcv) |
WO2005058821A1 (en) * | 2003-12-11 | 2005-06-30 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
JP2008505849A (ja) * | 2004-02-04 | 2008-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特に、hcv、ns3−ns4aプロテアーゼの阻害剤 |
DE602005015834D1 (de) * | 2004-02-27 | 2009-09-17 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
CN1946691A (zh) * | 2004-02-27 | 2007-04-11 | 先灵公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物 |
RU2006134000A (ru) * | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с |
JP4714732B2 (ja) * | 2004-02-27 | 2011-06-29 | シェーリング コーポレイション | C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての硫黄化合物 |
US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
EP1730165A1 (en) * | 2004-02-27 | 2006-12-13 | Schering Corporation | Inhibitors of hepatitis c virus ns3 protease |
AR049635A1 (es) * | 2004-05-06 | 2006-08-23 | Schering Corp | (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c |
JP2008501802A (ja) * | 2004-06-08 | 2008-01-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
CA2577812A1 (en) * | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005286727A1 (en) * | 2004-09-23 | 2006-03-30 | Wyeth | Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus |
EP2374464A3 (en) * | 2004-10-01 | 2011-10-26 | Vertex Pharmaceuticals Incorporated | HCV N3S-NS4A protease inhibition |
TW201424733A (zh) * | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
PL1891089T3 (pl) * | 2005-06-02 | 2015-05-29 | Merck Sharp & Dohme | Inhibitory proteazy HCV w połączeniu z pokarmem |
US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
WO2007016589A2 (en) * | 2005-08-02 | 2007-02-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
MX2008013136A (es) * | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores del virus de hepatitis que comprenden beta-aminoacidos y sus usos. |
AU2007238253A1 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | HCV inhibitors |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
UA100666C2 (uk) * | 2006-04-11 | 2013-01-25 | Новартіс Аг | Інгібітори нсv/віл та їх застосування |
WO2008059367A1 (en) | 2006-11-14 | 2008-05-22 | Pfizer Products Inc. | Penem prodrugs |
PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
EP2199282A4 (en) | 2007-10-10 | 2011-04-27 | Takeda Pharmaceutical | AMIDE COMPOUND |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
UA100527C2 (en) | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
-
2008
- 2008-10-08 CN CN200880110944.7A patent/CN101868452B/zh not_active Expired - Fee Related
- 2008-10-08 JP JP2010528385A patent/JP5095824B2/ja not_active Expired - Fee Related
- 2008-10-08 AU AU2008309589A patent/AU2008309589B2/en not_active Ceased
- 2008-10-08 MX MX2010003916A patent/MX2010003916A/es active IP Right Grant
- 2008-10-08 CA CA2702132A patent/CA2702132A1/en not_active Abandoned
- 2008-10-08 AR ARP080104396A patent/AR068756A1/es not_active Application Discontinuation
- 2008-10-08 BR BRPI0817881 patent/BRPI0817881A2/pt not_active IP Right Cessation
- 2008-10-08 CN CN201410273335.0A patent/CN104016970A/zh active Pending
- 2008-10-08 EP EP08805142A patent/EP2205584A1/en not_active Withdrawn
- 2008-10-08 EA EA201000556A patent/EA020951B1/ru not_active IP Right Cessation
- 2008-10-08 KR KR1020107007789A patent/KR101218882B1/ko not_active IP Right Cessation
- 2008-10-08 KR KR1020127015695A patent/KR101396696B1/ko not_active IP Right Cessation
- 2008-10-08 WO PCT/EP2008/063460 patent/WO2009047264A1/en active Application Filing
- 2008-10-09 PE PE2008001744A patent/PE20091237A1/es not_active Application Discontinuation
- 2008-10-09 TW TW097139071A patent/TW200932737A/zh unknown
- 2008-10-09 CL CL2008002995A patent/CL2008002995A1/es unknown
- 2008-10-10 US US12/249,186 patent/US8008263B2/en not_active Expired - Fee Related
-
2010
- 2010-03-04 ZA ZA2010/01585A patent/ZA201001585B/en unknown
- 2010-03-11 CR CR11310A patent/CR11310A/es not_active Application Discontinuation
- 2010-03-26 TN TNP2010000137A patent/TN2010000137A1/fr unknown
- 2010-04-08 MA MA32757A patent/MA31767B1/fr unknown
- 2010-04-30 CO CO10051497A patent/CO6270317A2/es not_active Application Discontinuation
-
2011
- 2011-07-19 US US13/185,683 patent/US8222425B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ZA201001585B (en) | 2010-12-29 |
EA201000556A1 (ru) | 2010-10-29 |
EA020951B1 (ru) | 2015-03-31 |
CO6270317A2 (es) | 2011-04-20 |
WO2009047264A1 (en) | 2009-04-16 |
CL2008002995A1 (es) | 2009-06-26 |
AU2008309589B2 (en) | 2012-07-05 |
AR068756A1 (es) | 2009-12-02 |
EP2205584A1 (en) | 2010-07-14 |
US20110275819A1 (en) | 2011-11-10 |
CN101868452A (zh) | 2010-10-20 |
TN2010000137A1 (en) | 2011-09-26 |
AU2008309589A1 (en) | 2009-04-16 |
KR20120094049A (ko) | 2012-08-23 |
CN104016970A (zh) | 2014-09-03 |
MA31767B1 (fr) | 2010-10-01 |
PE20091237A1 (es) | 2009-09-14 |
CR11310A (es) | 2010-05-06 |
US8222425B2 (en) | 2012-07-17 |
US8008263B2 (en) | 2011-08-30 |
KR20100051749A (ko) | 2010-05-17 |
CA2702132A1 (en) | 2009-04-16 |
CN101868452B (zh) | 2014-08-06 |
TW200932737A (en) | 2009-08-01 |
KR101218882B1 (ko) | 2013-01-07 |
KR101396696B1 (ko) | 2014-05-16 |
BRPI0817881A2 (pt) | 2015-03-31 |
US20090137495A1 (en) | 2009-05-28 |
JP5095824B2 (ja) | 2012-12-12 |
JP2011500528A (ja) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2010000137A1 (en) | Spiropyrrolidines and their use against hcv and hiv infection | |
TNSN08400A1 (en) | Organic compounds and their uses | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
TN2011000482A1 (en) | Organic compounds and their uses | |
EA201100505A1 (ru) | Органические соединения для применения для лечения бактериальных инфекций | |
WO2007121125A3 (en) | Hcv inhibitors | |
MX2009011002A (es) | Composiciones de proteccion de isquemia/reperfusion y metodos de uso. | |
EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS | |
WO2010002877A3 (en) | Bycyclic nucleosides and nucleotides as therapeutic agents | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
MY161495A (en) | Virus like particle compositions and methods of use | |
MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
IN2012DN00624A (es) | ||
EP2192901A4 (en) | CHEMICAL AGENTS, COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND RELATED DISEASES | |
TNSN08496A1 (en) | Aminothiazoles and their uses | |
WO2007121124A3 (en) | Hcv inhibitors comprising beta amino acids and their uses | |
TN2011000204A1 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
WO2010074936A3 (en) | Enzastaurin for the treatment of cancer | |
EP2224943A4 (en) | USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS | |
EP2207555A4 (en) | NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF | |
WO2008033389A3 (en) | Macrocyclic hcv inhibitors and their uses | |
WO2009068682A3 (en) | Phenyl-oxetanyl-derivatives | |
WO2007076091A3 (en) | Treatment of viral infections using a tissue factor inhibitor | |
MX2013003903A (es) | Nuevos tratamientos de infeccion por el virus de hepatitis c. | |
TN2009000495A1 (en) | Macrocycles and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |